## Abstract ## Background Due to severe side effects in virtually all children treated with a standard dose of 45 mg/m^2^/day allβ__trans__βretinoic acid (ATRA) for acute promyelocytic leukemia (APL) the AMLβBFM study group reduced the dosage to 25 mg/m^2^/day. For the lack of data on the use of A
Acute promyelocytic leukemia in children
β Scribed by Chan, Ka Wah ;Steinherz, Peter G. ;Miller, Denis R.
- Publisher
- John Wiley and Sons
- Year
- 1981
- Tongue
- English
- Weight
- 737 KB
- Volume
- 9
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Sixteen children (ages 2β17) with acute promyelocytic leukemia (APL) were studied retrospectively. Diagnosis was based on clinical features and morphological criteria of the FAB classification. Bleeding diathesis was the predominant presenting symptom (>85%), associated with laboratory findings of disseminated intravascular coagulation (DIC). Extramedullary manifestations included skin rash in six patients, gum infiltration in two, and meningeal leukemia in two. Induction therapy consisted of cytosine arabinoside and an anthracycline, with or without other agents. Prophylactic heparinization was given to 12 patients. Six patients (37.5%) failed to achieve remission and died, secondary to hemorrhage in three, and secondary to infection in the remaining three patients. The median duration of remission was 14 months, and the median survival for responders was 21 months. One meningeal leukemia preceded bone marrow relapse despite intermittent intrathecal chemotherapy for prophylaxis. Three patients remain in continuous complete remission 3 years after initial diagnosis.
Although childhood APL shares many features of its adult counterpart, the high frequency of extramedullary manifestations and mortality secondary to neutropenia deserves separate attention.
π SIMILAR VOLUMES
We report on two girls, 3 and 13 years well tolerated, although both children were old, with acute promyelocytic leukemia critically ill. They achieved a complete remis-(APL) who were successfully treated with all-sion confirmed by light microscopy, but trans retinoic acid (ATRA) 45 mg/m\*/day. reve
## BACKGROUND. Extramedullary acute promyelocytic leukemia (APL) is rare, and said to be more common after treatment with all-trans retinoic acid (ATRA) than after any other treatment. ## METHODS. The case of a child with extramedullary relapse of APL after initial treatment with ATRA and that